Definitive Contract 75N93021C00021

Award Date 5/17/21

Potential Completion Date 12/16/25

Potential Value $17M

Federal Agency

National Institute of Allergy and Infectious Diseases

Awardee

Abvacc, Inc.

Ultimate Awardee

Not listed

NAICS Category

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

PSC Category

AN11 - Health R&D Services; Health Care Services; Basic Research

Federal Contract Vehicle

Set-Aside Type

No Set-Aside Used

Extent Competed

Full and Open Competition

Major Defense Program

Not listed

Pricing Type

Cost Plus Fixed Fee

Place of Performance

Potomac, MD 20850, USA

Solicitation Procedures

Negotiated Proposal / Quote

Number Of Offers Received

Legislative Mandate

Employment Eligibility Verification

National Interest Action

Not listed

Research Type

Not listed

Primary Consortia Member

Not listed

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $16,905,516 cost-plus-fixed-fee definitive contract to Abvacc, Inc., a for-profit biotechnology company, to develop a potent therapeutic monoclonal antibody against the Marburg virus. This contract falls under NIAID's Omnibus Broad Agency Announcement (BAA) for medical countermeasure development, which solicits proposals across various infectious disease research areas, including vaccines, therapeutics, and diagnostics for biodefense and emerging threats. The contract has a performance period through December 16, 2025 and is being executed in Potomac, Maryland. Abvacc has received several prior NIAID awards, including research grants to advance Marburg virus vaccine and therapeutic candidates.

Generated 7/10/24, 9:03 AM

Name	Solicitation Number	Federal Agency	Type	Posted Date (Click to sort descending)
2020 NIAID Omnibus Broad Agency Announcement	HHS-NIH-NIAID-BAA2020-1	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Solicitation 2/11	1/3/20, 11:53 AM
2020 NIAID Omnibus Broad Agency Announcement	HHS-NIH-NIAID-BAA2020-1	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Award Notice 10/11	5/12/21, 1:53 PM
HHS-NIH-NIAID-BAA2020-1: Research Area 002, Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis Associated with Enterovirus D68	HHS-NIH-NIAID-BAA2020-1	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Award Notice 3/11	8/20/20, 5:35 PM
COVID-19: HHS-NIH-NIAID-BAA2020-1: Research Area 003, Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases	HHS-NIH-NIAID-BAA2020-1	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Award Notice 4/11	8/21/20, 3:52 PM
2020 NIAID Omnibus Broad Agency Announcement	HHS-NIH-NIAID-BAA2020-1	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Pre-Solicitation 1/11	12/11/19, 10:13 AM

Mod #	Reason For Modification	Federal Obligation (Click to sort descending)	Date (Click to sort ascending)
P00009	Other Administrative Action	$0	7/9/24
P00008	Other Administrative Action	$0	2/28/24
P00007	Other Administrative Action	$0	8/1/23
P00006	Funding Only Action	$69.2k	4/26/23
P00005	Novation Agreement	$0	3/27/23

Plans
Login

Blog